Skip to main content
. 2019 Jan 10;4(1):e124643. doi: 10.1172/jci.insight.124643

Figure 6. Ranolazine-mediated reductions in body weight are not required for ranolazine’s salutary actions on NAFLD and dysglycemia.

Figure 6

(A) Pyruvate tolerance and associated AUC. (B) Liver TAG content and (C) body weights in obese mice treated acutely with either vehicle control (VC) or ranolazine (Ran) (n = 4). (D) Pyruvate tolerance and associated AUC. (E) Liver TAG content and (F) body weights in obese mice treated with either VC or Ran for 1 week (n = 5–6). Values represent means ± SEM. Differences were determined with an unpaired, 2-tailed Student’s t test or a 2-way ANOVA, followed by a Bonferroni post hoc analysis. *P < 0.05, significantly different from VC-treated counterpart.